X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
male (4) 4
cancer (3) 3
carcinoma, renal cell - therapy (3) 3
cyclophosphamide (3) 3
female (3) 3
humans (3) 3
index medicus (3) 3
kidney neoplasms - therapy (3) 3
regulatory t-cells (3) 3
behavioral sciences (2) 2
cancer vaccines (2) 2
cancer vaccines - therapeutic use (2) 2
carcinoma, renal cell - immunology (2) 2
colony-stimulating factor (2) 2
computer simulation (2) 2
granulocyte-macrophage colony-stimulating factor - therapeutic use (2) 2
hematology, oncology and palliative medicine (2) 2
immunotherapy (2) 2
kidney neoplasms - immunology (2) 2
middle aged (2) 2
odor detection (2) 2
peptides (2) 2
pulsed dendritic cells (2) 2
rat (2) 2
receptors (2) 2
research (2) 2
vaccines (2) 2
vaccines, subunit - therapeutic use (2) 2
3-dimensional model (1) 1
5 fluorouracil (1) 1
5-fu (1) 1
5-fu, 5 fluorouracil (1) 1
adverse event (1) 1
ae, adverse event (1) 1
aged (1) 1
animals (1) 1
anosmia (1) 1
antigens (1) 1
antigens, neoplasm - immunology (1) 1
apolipoprotein a-i - blood (1) 1
atmospheric and oceanic physics (1) 1
atmospheric chemistry (1) 1
augmented reality (1) 1
biochemistry & molecular biology (1) 1
biomarkers (1) 1
biotechnology & applied microbiology (1) 1
bisphosphonates (1) 1
bone pain (1) 1
bulb (1) 1
bulbectomy (1) 1
cancer vaccine (1) 1
cancer vaccines - administration & dosage (1) 1
cancer vaccines - adverse effects (1) 1
cancer vaccines - immunology (1) 1
carcinoma (1) 1
carcinoma, renal cell (1) 1
carcinoma, renal cell - blood (1) 1
carcinoma, renal cell - drug therapy (1) 1
carcinoma, renal cell - mortality (1) 1
carcinoma, renal cell - pathology (1) 1
care and treatment (1) 1
ccrcc (1) 1
ccrcc, clear cell renal cell carcinoma (1) 1
cd8-positive t-lymphocytes - immunology (1) 1
cell biology (1) 1
change of odor quality (1) 1
channel (1) 1
checkpoint inhibitor (1) 1
chemokine ccl17 - blood (1) 1
chemoreception (1) 1
chemoreceptor cells - drug effects (1) 1
chiral molecules (1) 1
chlorofluorocarbons (1) 1
cilia (1) 1
clear cell renal cell carcinoma (1) 1
climate (1) 1
clinical trials (1) 1
college faculty (1) 1
combined modality therapy (1) 1
concanavalin a (1) 1
concanavalin a - pharmacology (1) 1
consciousness raising (1) 1
ctl (1) 1
ctl, cytotoxic t-lymphocyte (1) 1
cy, cyclophosphamide (1) 1
cyclophosphamide - administration & dosage (1) 1
cyclophosphamide - pharmacology (1) 1
cyclophosphamide - therapeutic use (1) 1
cytokines (1) 1
cytotoxic t-lymphocyte (1) 1
dc, dendritic cell (1) 1
dcr (1) 1
dcr, disease control rate (1) 1
dendritic cell (1) 1
dendritic cells (1) 1
depletion (1) 1
deprivation (1) 1
dipoles (1) 1
discrimination learning - drug effects (1) 1
disease control rate (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1599 - 1611
Journal Article
Nature Medicine, ISSN 1078-8956, 08/2012, Volume 18, Issue 8, pp. 1254 - 1261
IMA901 is the first therapeutic vaccine for renal cell cancer (RCC) consisting of multiple tumor-associated peptides (TUMAPs) confirmed to be naturally... 
MEDICINE, RESEARCH & EXPERIMENTAL | PULSED DENDRITIC CELLS | COLONY-STIMULATING FACTOR | HIGH-FREQUENCIES | BIOCHEMISTRY & MOLECULAR BIOLOGY | MELANOMA PATIENTS | RENAL-CELL CARCINOMA | TUMOR-ANTIGEN | CELL BIOLOGY | MYELOID SUPPRESSOR-CELLS | PROSTATE-CANCER | REGULATORY T-CELLS | PEPTIDE VACCINE | Predictive Value of Tests | Cyclophosphamide - administration & dosage | Prognosis | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Kidney Neoplasms - immunology | Immunotherapy, Active | Male | Lymphocyte Depletion | Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use | Carcinoma, Renal Cell - immunology | Cyclophosphamide - therapeutic use | Kidney Neoplasms - blood | T-Lymphocytes, Regulatory - immunology | Cancer Vaccines - therapeutic use | Vaccines, Subunit - therapeutic use | Female | Carcinoma, Renal Cell - drug therapy | Immunosuppressive Agents - pharmacology | Chemokine CCL17 - blood | Immunosuppressive Agents - administration & dosage | Kidney Neoplasms - therapy | Carcinoma, Renal Cell - blood | HLA-A2 Antigen - immunology | Antigens, Neoplasm - immunology | Kaplan-Meier Estimate | Treatment Outcome | Combined Modality Therapy | T-Lymphocytes, Regulatory - drug effects | Cyclophosphamide - pharmacology | Biomarkers | Carcinoma, Renal Cell - therapy | CD8-Positive T-Lymphocytes - immunology | Kidney Neoplasms - drug therapy | Apolipoprotein A-I - blood | Cancer vaccines | Cyclophosphamide | Polypeptides | Immune response | Dosage and administration | Research | Health aspects | Kidney diseases | Peptides | Gene expression | Medical prognosis | Cancer | Immune system
Journal Article
Environmental Engineering and Management Journal, ISSN 1582-9596, 2017, Volume 16, Issue 3, pp. 587 - 595
Floods have long been the cause of severe human and economic loss. Structural measures are applied to minimize the consequences of these natural disasters. A... 
Flood control | Model Predictive Control | Hydrologic model | ENVIRONMENTAL SCIENCES | CHANNEL | IRRIGATION CANALS | INUNDATION | flood control | hydrologic model | MODEL-PREDICTIVE CONTROL | FLOW
Journal Article
Human Vaccines & Immunotherapeutics, ISSN 2164-5515, 11/2014, Volume 10, Issue 11, pp. 3179 - 3189
Despite a major improvement in the treatment of advanced kidney cancer by the recent introduction of targeted agents such as multi-kinase inhibitors, long-term... 
PR, Partial response | intradermally | MSKCC, Memorial Sloan Kettering Cancer Center | RECIST, Response Evaluation Criteria in Solid Tumors | CY, Cyclophosphamide | GM-CSF | NCI-CTC, National Cancer Institute-Common Toxicity Criteria | cyclophosphamide | 5-FU, 5 fluorouracil | mg, Milligram | PFS, Progression-free survival | PK, Pharmacokinetic | Tregs, Regulatory T-cells | HLA, Human leukocyte antigen | DC, Dendritic cell | SAE, Serious adverse event | kidney cancer | TUMAP, Tumor-associated peptides | SD, Stable disease | ECG, Electrocardiogram | mTOR, Mammalian target of rapamycin | HBV, Hepatitis B virus | PD, Progressive disease | vaccination | mRNA, Messenger ribonucleic acid | OS, Overall survival | MHC, Major histocompatibility complex | MDSC, Myeloid-derived suppressor cells | DCR, Disease control rate | ELISpot, Enzyme-linked immunospot assay | CTL, Cytotoxic T-lymphocyte | IMA901 | immunotherapy | tumor-associated peptides | checkpoint inhibitor | IL, Interleukin | Cancer vaccine | RCC, Renal cell carcinoma | s.c., subcutaneous, subcutaneously | FDA, Food and Drug Administration | n, Number | ccRCC, Clear cell renal cell carcinoma | μg, Microgram | VEGF, Vascular endothelial growth factor | renal cell carcinoma | AE, Adverse event | IFN, Interferon | i.d., intradermal | TNF, Tumor necrosis factor | TKI, Tyrosine-kinase inhibitors | Checkpoint inhibitor | Cyclophosphamide | Renal cell carcinoma | Immunotherapy | Vaccination | Kidney cancer | Tumor-associated peptides | Partial response | MDSC | Myeloid-derived suppressor cells | MHC | Response Evaluation Criteria in Solid Tumors | IMMUNOLOGY | TNF | subcutaneous | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | Human leukocyte antigen | mTOR | HISTOLOGIC SUBTYPES | Hepatitis B virus | PFS | HBV | Vascular endothelial growth factor | Food and Drug Administration | Progressive disease | Dendritic cell | RECIST | PULSED DENDRITIC CELLS | Adverse event | Clear cell renal cell carcinoma | Pharmacokinetic | subcutaneously | DCR | Major histocompatibility complex | RCC | TKI | Microgram | Tumor necrosis factor | Electrocardiogram | SAE | Mammalian target of rapamycin | Enzyme-linked immunospot assay | HLA | Overall survival | Progression-free survival | FDA | Interleukin | 5 fluorouracil | mRNA | Tyrosine-kinase inhibitors | NCI-CTC | ELISpot | intradermal | IFN | Milligram | GM-CSF GENE | Stable disease | Number | Serious adverse event | TUMAP | Messenger ribonucleic acid | MSKCC | Tregs | VEGF | Cytotoxic T-lymphocyte | ECG | Disease control rate | SIPULEUCEL-T | Regulatory T-cells | ccRCC | National Cancer Institute-Common Toxicity Criteria | DOUBLE-BLIND | CTL | Interferon | Memorial Sloan Kettering Cancer Center | CARCINOMA | 5-FU | Immunotherapy - methods | Humans | Kidney Neoplasms - immunology | Male | Vaccines, Subunit - immunology | Granulocyte-Macrophage Colony-Stimulating Factor - therapeutic use | Carcinoma, Renal Cell - immunology | Cancer Vaccines - immunology | Cancer Vaccines - therapeutic use | Lymphocyte Activation - immunology | Vaccines, Subunit - therapeutic use | Carcinoma, Renal Cell - therapy | Female | T-Lymphocytes - immunology | Kidney Neoplasms - therapy
Journal Article
Supportive Cancer Therapy, ISSN 1543-2912, 09/2007, Volume 4, Issue 4, pp. 203 - 210
Bone metastases might lead to severe bone pain, pathologic fractures, and hypercalcemia. Osteolytic destruction is caused by the activation of osteoclasts by... 
Visual analog scale | Symptom improvement | Bisphosphonates | Bone pain
Journal Article
Behavioural Processes, ISSN 0376-6357, 1999, Volume 48, Issue 1, pp. 89 - 99
Olfaction is one of the most important sensory systems for many mammalian species. Yet, the extent to which olfactory stimuli control the behaviour of a... 
Lectin | Reversibility | Odor inhibition | Wistar rat | Odor detection | RAT | lectin | CILIA | LESIONS | odor detection | ZOOLOGY | EPITHELIUM | DEPRIVATION | reversibility | odor inhibition | BEHAVIORAL SCIENCES | ANOSMIA | PSYCHOLOGY, BIOLOGICAL | BULBECTOMY | RECEPTORS | ZNSO4 | OLFACTORY BULB REMOVAL | Concanavalin A
Journal Article
DPA International (German), 08/2019
Newspaper Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.